"Replicate Bioscience's Breakthrough in Combatting Mono-Causing Virus with srRNA Technology"
TL;DR Summary
Replicate Bioscience, a San Diego startup, has reported positive results from an 84-person clinical trial of its experimental mRNA rabies vaccine, indicating potential for stronger immunity with smaller doses. CEO Nathaniel Wang plans to raise a Series B round based on the data but acknowledges the need for a pharmaceutical or government partner to advance the vaccine into larger studies.
Topics:health#clinical-trial#healthtech#immunization#mrna-vaccine-technology#rabies-shot#replicate-bioscience
- Replicate Bioscience takes aim at mono-causing virus after promising results with mRNA rabies shot Endpoints News
- Replicate's self-replicating RNA rabies vaccine clears phase 1 FierceBiotech
- Readout Newsletter: Replicate, Biogen's Leqembi, and Humira STAT
- Replicate Bioscience Announces Positive Initial Clinical Results for its Next Generation srRNA Technology PR Newswire
- Replicate's rabies vaccine demonstrates effectiveness in Phase I trial Clinical Trials Arena
Reading Insights
Total Reads
0
Unique Readers
12
Time Saved
0 min
vs 1 min read
Condensed
47%
113 → 60 words
Want the full story? Read the original article
Read on Endpoints News